Navegando por Orientadores "MONTENEGRO, Raquel Carvalho"

Agora exibindo 1 - 2 de 2

Acesso aberto (Open Access)
Avaliação do potencial biotecnológico de compostos isolados de Swietenia macrophylla no tratamento de câncer
(Universidade Federal do Pará, 2015-11-30) BARRETO, Leilane de Holanda; MONTENEGRO, Raquel Carvalho; http://lattes.cnpq.br/0043828437326839
Swietenia macrophylla (mahogany) is a species of plant widely known for its therapeutic potential. The main constituents isolated extracts of this plant are structures known as limonoids. The limonoids also have several biological activities, among them, antitumor activity. The aim of this study was to evaluate the antitumor potential of the extract and limonoid obtained from leaves of S. macrophylla in cancer cell lines. Cytotoxicity to 5 cancer cell lines and normal revealed that the extract had cytotoxic effect in colorectal cancer cell lines (HCT-116 and HT-29), as the limonoids were cytotoxic for colorectal cancer (HCT-116) and melanoma (SKMEL-19). Given these results, we selected the limonoid L3 and HCT-116 cell line to evaluate the mechanism of action, as well as the HT-29 lineage, which has the TP53 gene mutated for comparison as possible of the compound mechanism of action, once it was less sensitive to L3. Moreover, L3 showed more selective for tumor cells. None of the compounds caused hemolysis of erythrocytes in mice. To evaluate the antiproliferative action of L3, the clonogenic assay was performed, where the two lines there was a significant reduction of colonies, however this reduction was more significant in HCT-116. The L3 compound also has caused death by apoptosis in a dose-dependent manner in the lines, where the number of cells in apoptosis was higher in HCT-116. To evaluate DNA damage, it was held the comet assay, which showed that L3 cause damage to the DNA of the two cancer cell lines, with greater damage index in HCT-116. The assessment of cell cycle distribution of cells after treatment with L3 showed that there was blocking the cycle at the G2 / M phase, mainly in HCT-116 (45% of the cells). From these data, it conducted a study of genes involved in this phase of the cycle, from analysis of their expression by RT-PCR. The ATM gene, which is activated by DNA damage activates the CHK-2 which in turn phosphorylates p53 protein. p53 protein can activate the transcription of p21 gene, which triggers cell cycle stopped, or activate cell death pathways. In this study, we found increased expression of genes ATM, CHK-2, TP53, ARF in a dose dependent in both cacer cell lines, and this expression was higher in HCT-116 cell line. The expression of p21 was increased in HCT-116, while in HT-29 decreased, this is due to the fact that HT-29 possess the mutant TP53 gene, then your protein does not work properly. As the path of apoptosis was evaluated caspase-3 gene and the anti-apoptotic gene BCL-2. There was increase in the expression of caspase-3 mainly in HCT-116 and decrease of BCL-2. These results suggest that L3 may be causing damage to the DNA of cells, triggering a cellular signaling pathway dependent on p53. To evaluate the toxicity of S. macrophylla extract, it was held the acute toxicology testing in mice, where the extract did not cause any changes in the physiological parameters of animals. As the claustogenicidade test (micronucleus) also showed that the extract is not mutagenic in the mouse bone marrow cells.
Acesso aberto (Open Access)
Polimorfismo do Gene UGT1A1 associado à toxicidade em pacientes oncológicos tratados com irinotecano (CPT-11) em Belém/PA
(Universidade Federal do Pará, 2015-03-23) CARRERA, Jackeline de Sousa; MONTENEGRO, Raquel Carvalho; http://lattes.cnpq.br/0043828437326839
Introduction: Studies and reviews the international scientific literature have gathered data to support the role of pharmacogenomics in clinical medicine, specifically genotype UGT1A1*28 and UGT1A1*6 as predictors of toxicity associated with therapy with CPT-11 (irinotecan), because an insert thymine-adenine in the promoter region of the UGT1A1 gene TATAbox or a single nucleotide polymorphism in exon 1 of the same gene, causing lesser extent UGT1A1 enzyme and hence lower glucuronidation of the drug. Objective: To investigate the occurrence of polymorphisms in the promoter region of the UGT1A1 gene and associate their presence with the toxicities of manifestation to CPT-11 drug in cancer patients treated at two public hospitals specialized in oncology in Belém /PA. Method: Patients in cancer treatment to CPT-11 base were accompanied by pharmacotherapeutic monitoring method as the occurrence of toxicities. Adverse reactions were assessed according to the National Cancer Institute Common Toxicity Criteria for Adverse Events, Version 4.0. The study also analyzed the genetic material of patients, the frequency and distribution of the polymorphism in the UGT1A1 gene by polymerase chain reaction and sequencing. As they could also be evaluated clinical and epidemiological data of the subjects. Results: A total of 31 patients were recruited, the majority (80.6%) treated with modified IFL regimen (120 mg /m² CPT-11), the most frequent gender was female (54.8%) and the primary site of the tumor , predominantly, it was the rectum (41.9%). Among the 27 patients could be genotyped none showed polymorphism in exon 1 (UGT1A1 * 6), but the following alleles were detected as the TATA promoter polymorphism in the gene, TA5/6 (3.7%), TA6/6 (44 , 4%), TA6/7 (37%) and TA7/7 (14.8%). A total of 71 toxicities were observed in 25 patients. The study population is in Hardy-Weinberg equilibrium (P = 0.135). Our study found no significant relationship between the different toxicities manifested in patients with different numbers of variant alleles, but it was observed that patients who had two alleles or a single variant allele had more medical interventions (dose reduction, delay or discontinuation of treatment) due to toxicity than patients in the wild-type allele (p = 0.016). Conclusion: The findings of this study showed a high frequency of adverse reactions to CPT-11 use in the studied patients, even low-dose protocols in relation to other studies, although they have not shown significant differences suggest the continuity of the same order to get larger sample size, considering that when the population was stratified by frequency of medical interventions motivated by toxicity, the carrier of the mutation group, heterozygous or homozygous, had higher intervention rate during treatment. Those patients can present toxicities more severe than compromise the continuity of care.